Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109564 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
A Phase 2 study, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 174
- Enrollment target
NCT00109564 is a Phase 2 study that has completed, run by Targacept. The registered enrollment target is 174 participants.
The verdict
NCT00109564, a Phase 2 study, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 174 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.
Interventions
- DRUG ispronicline (nicotinic acetylcholine receptor agonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109564
The ClinicalTrials.gov registry entry for NCT00109564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Targacept, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ispronicline (nicotinic acetylcholine receptor agonist) is the first listed.
NCT00109564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109564 about?
NCT00109564 is a clinical study titled "A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)". The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration a...
What is the current status of trial NCT00109564?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 174 participants. The study started on 2005-01. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00109564?
The interventions under investigation include: ispronicline (nicotinic acetylcholine receptor agonist) (DRUG).
Who is sponsoring clinical trial NCT00109564?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.